Concepedia

Author

Karen Schneck

Eli Lilly (United States)

Also Known As

K. Schneck, KAREN SCHNECK, Karen B Schneck, Karen B. Schneck, Karen Schneck, Kiley Schneck

22

Publications

420

Citations

10

H-Index

9

Concepts

All Affiliations

Eli Lilly (United States)Eli Lilly (Spain)
KS

About

Karen Schneck is an author at Eli Lilly (United States) specializing in diabetes, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

57

2

Diabetes

3

3

57

3

Pharmacology

3

3

57

4

Drug Discovery

1

1

16

5

Pharmacokinetic Modeling

1

1

17

Karen Schneck

×

10

Publications

394

Citations

10

H-Index

YearCitations

A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes

Peggy L. Barrington, Jenny Y. Chien, H. D. Hollis Showalter,

Diabetes Obesity and Metabolism

2011

109

LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, showed a dose‐dependent effect on insulin secretion in healthy subjects

Peggy L. Barrington, Jenny Y. Chien, Fabián Tibaldi,

Diabetes Obesity and Metabolism

2011

72

Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling

Maria M. Posada, James A. Bacon, Karen Schneck,

Drug Metabolism and Disposition

2014

57

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Chris H. Takimoto, Lisa A. Hammond-Thelin, Jane E. Latz,

Clinical Cancer Research

2007

47

Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model

Karen Schneck, Xin Zhang, Robert J. Bauer,

Journal of Pharmacokinetics and Pharmacodynamics

2012

24

Pemetrexed Safety and Pharmacokinetics in Patients with Third-Space Fluid

Nicolas Dickgreber, Jens Benn Sørensen, Luis G. Paz-Ares,

Clinical Cancer Research

2010

21

Modeling Pharmacokinetic Profiles of Insulin Regimens to Enhance Understanding of Subcutaneous Insulin Regimens

Lai Tham, Karen Schneck, Ali Ertekin,

The Journal of Clinical Pharmacology

2017

17

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide

Karen Schneck, Shweta Urva

CPT Pharmacometrics & Systems Pharmacology

2024

17

Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator

Xin Zhang, Karen Schneck, Juliana Bue‐Valleskey,

Journal of Pharmacokinetics and Pharmacodynamics

2012

16

Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies

Garrett R. Mullins, Michael E. Hodsdon, Ying Grace Li,

The Journal of Clinical Endocrinology & Metabolism

2023

14

Page 1